Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 118

1.

Deriving the optimal limit of detection for an HCV point-of-care test for viraemic infection: Analysis of a global dataset.

Freiman JM, Wang J, Easterbrook PJ, Horsburgh CR, Marinucci F, White LF, Kamkamidze G, Krajden M, Loarec A, Njouom R, Nguyen KV, Shiha G, Soliman R, Solomon SS, Tsertsvadze T, Denkinger CM, Linas B.

J Hepatol. 2019 Jul;71(1):62-70. doi: 10.1016/j.jhep.2019.02.011. Epub 2019 Feb 21.

PMID:
30797050
2.

Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial.

Paton NI, Kityo C, Thompson J, Nankya I, Bagenda L, Hoppe A, Hakim J, Kambugu A, van Oosterhout JJ, Kiconco M, Bertagnolio S, Easterbrook PJ, Mugyenyi P, Walker AS; Europe Africa Research Network for Evaluation of Second-line Therapy (EARNEST) Trial Team.

Lancet HIV. 2017 Aug;4(8):e341-e348. doi: 10.1016/S2352-3018(17)30065-6. Epub 2017 May 8.

3.

Diagnosis of viral hepatitis.

Easterbrook PJ, Roberts T, Sands A, Peeling R.

Curr Opin HIV AIDS. 2017 May;12(3):302-314. doi: 10.1097/COH.0000000000000370. Review.

4.

HIV Drug Resistance Mutations in Non-B Subtypes After Prolonged Virological Failure on NNRTI-Based First-Line Regimens in Sub-Saharan Africa.

Kityo C, Thompson J, Nankya I, Hoppe A, Ndashimye E, Warambwa C, Mambule I, van Oosterhout JJ, Wools-Kaloustian K, Bertagnolio S, Easterbrook PJ, Mugyenyi P, Walker AS, Paton NI; Europe Africa Research Network for Evaluation of Second-line Therapy (EARNEST) Trial Team.

J Acquir Immune Defic Syndr. 2017 Jun 1;75(2):e45-e54. doi: 10.1097/QAI.0000000000001285.

5.

Epidemiology of Hepatitis B Virus Infection and Impact of Vaccination on Disease.

Nelson NP, Easterbrook PJ, McMahon BJ.

Clin Liver Dis. 2016 Nov;20(4):607-628. doi: 10.1016/j.cld.2016.06.006. Review. Erratum in: Clin Liver Dis. 2017 May;21(2):xiii.

6.

Who to test and how to test for chronic hepatitis C infection - 2016 WHO testing guidance for low- and middle-income countries.

Easterbrook PJ; WHO Guidelines Development Group.

J Hepatol. 2016 Oct;65(1 Suppl):S46-S66. doi: 10.1016/j.jhep.2016.08.002. Review.

PMID:
27641988
7.

Hepatitis C: global epidemiology and strategies for control.

Lanini S, Easterbrook PJ, Zumla A, Ippolito G.

Clin Microbiol Infect. 2016 Oct;22(10):833-838. doi: 10.1016/j.cmi.2016.07.035. Epub 2016 Aug 11. Review.

8.

Hepatitis C Core Antigen Testing for Diagnosis of Hepatitis C Virus Infection: A Systematic Review and Meta-analysis.

Freiman JM, Tran TM, Schumacher SG, White LF, Ongarello S, Cohn J, Easterbrook PJ, Linas BP, Denkinger CM.

Ann Intern Med. 2016 Sep 6;165(5):345-55. doi: 10.7326/M16-0065. Epub 2016 Jun 21. Review.

9.

Wide variation in estimates of global prevalence and burden of chronic hepatitis B and C infection cited in published literature.

Basnayake SK, Easterbrook PJ.

J Viral Hepat. 2016 Jul;23(7):545-59. doi: 10.1111/jvh.12519. Epub 2016 Mar 30. Review.

PMID:
27028545
10.

CD41 T cell recovery during suppression of HIV replication: an international comparison of the immunological efficacy of antiretroviral therapy in North America, Asia and Africa.

Geng EH, Neilands TB, Thièbaut R, Bwana MB, Nash D, Moore RD, Wood R, Zannou DM, Althoff KN, Lim PL, Nachega JB, Easterbrook PJ, Kambugu A, Little F, Nakigozi G, Nakanjako D, Kiggundu V, Ki Li PC, Bangsberg DR, Fox MP, Prozesky H, Hunt PW, Davies MA, Reynolds SJ, Egger M, Yiannoutsos CT, Vittinghoff EV, Deeks SG, Martin JN.

Int J Epidemiol. 2015 Feb;44(1):251-63.

11.

Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models.

Eaton JW, Menzies NA, Stover J, Cambiano V, Chindelevitch L, Cori A, Hontelez JA, Humair S, Kerr CC, Klein DJ, Mishra S, Mitchell KM, Nichols BE, Vickerman P, Bakker R, Bärnighausen T, Bershteyn A, Bloom DE, Boily MC, Chang ST, Cohen T, Dodd PJ, Fraser C, Gopalappa C, Lundgren J, Martin NK, Mikkelsen E, Mountain E, Pham QD, Pickles M, Phillips A, Platt L, Pretorius C, Prudden HJ, Salomon JA, van de Vijver DA, de Vlas SJ, Wagner BG, White RG, Wilson DP, Zhang L, Blandford J, Meyer-Rath G, Remme M, Revill P, Sangrujee N, Terris-Prestholt F, Doherty M, Shaffer N, Easterbrook PJ, Hirnschall G, Hallett TB.

Lancet Glob Health. 2014 Jan;2(1):e23-34. doi: 10.1016/S2214-109X(13)70172-4. Epub 2013 Dec 10.

12.

Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models.

Eaton JW, Menzies NA, Stover J, Cambiano V, Chindelevitch L, Cori A, Hontelez JA, Humair S, Kerr CC, Klein DJ, Mishra S, Mitchell KM, Nichols BE, Vickerman P, Bakker R, Bärnighausen T, Bershteyn A, Bloom DE, Boily MC, Chang ST, Cohen T, Dodd PJ, Fraser C, Gopalappa C, Lundgren J, Martin NK, Mikkelsen E, Mountain E, Pham QD, Pickles M, Phillips A, Platt L, Pretorius C, Prudden HJ, Salomon JA, van de Vijver DA, de Vlas SJ, Wagner BG, White RG, Wilson DP, Zhang L, Blandford J, Meyer-Rath G, Remme M, Revill P, Sangrujee N, Terris-Prestholt F, Doherty M, Shaffer N, Easterbrook PJ, Hirnschall G, Hallett TB.

Lancet Glob Health. 2013 Dec 10;2(1):23-34.

13.

Assessment of second-line antiretroviral regimens for HIV therapy in Africa.

Paton NI, Kityo C, Hoppe A, Reid A, Kambugu A, Lugemwa A, van Oosterhout JJ, Kiconco M, Siika A, Mwebaze R, Abwola M, Abongomera G, Mweemba A, Alima H, Atwongyeire D, Nyirenda R, Boles J, Thompson J, Tumukunde D, Chidziva E, Mambule I, Arribas JR, Easterbrook PJ, Hakim J, Walker AS, Mugyenyi P; EARNEST Trial Team.

N Engl J Med. 2014 Jul 17;371(3):234-47. doi: 10.1056/NEJMoa1311274.

14.

Developing the 2013 WHO consolidated antiretroviral guidelines.

Easterbrook PJ, Irvine CJ, Vitoria M, Shaffer N, Muhe LM, Negussie EK, Doherty MC, Ball A, Hirnschall G.

AIDS. 2014 Mar;28 Suppl 2:S93-100. doi: 10.1097/QAD.0000000000000253. No abstract available.

PMID:
24849484
15.

The impact and cost of the 2013 WHO recommendations on eligibility for antiretroviral therapy.

Stover J, Gopalappa C, Mahy M, Doherty MC, Easterbrook PJ, Weiler G, Ghys PD.

AIDS. 2014 Mar;28 Suppl 2:S225-30. doi: 10.1097/QAD.0000000000000235.

PMID:
24849482
16.

Adoption of national recommendations related to use of antiretroviral therapy before and shortly following the launch of the 2013 WHO consolidated guidelines.

Nelson LJ, Beusenberg M, Habiyambere V, Shaffer N, Vitoria MA, Montero RG, Easterbrook PJ, Doherty MC.

AIDS. 2014 Mar;28 Suppl 2:S217-24. doi: 10.1097/QAD.0000000000000239.

PMID:
24849481
17.

Community and service provider views to inform the 2013 WHO consolidated antiretroviral guidelines: key findings and lessons learnt.

Hsieh AC, Mburu G, Garner AB, Teltschik A, Ram M, Mallouris C, Penazzato M, Shaffer N, Easterbrook PJ, Ball A.

AIDS. 2014 Mar;28 Suppl 2:S205-16. doi: 10.1097/QAD.0000000000000251.

PMID:
24849480
18.

Predicting treatment failure in adults and children on antiretroviral therapy: a systematic review of the performance characteristics of the 2010 WHO immunologic and clinical criteria for virologic failure.

Rutherford GW, Anglemyer A, Easterbrook PJ, Horvath T, Vitoria M, Penazzato M, Doherty MC.

AIDS. 2014 Mar;28 Suppl 2:S161-9. doi: 10.1097/QAD.0000000000000236. Review.

PMID:
24849476
19.

Optimal strategies for monitoring response to antiretroviral therapy in HIV-infected adults, adolescents, children and pregnant women: a systematic review.

Tucker JD, Bien CH, Easterbrook PJ, Doherty MC, Penazzato M, Vitoria M, Peeling RW.

AIDS. 2014 Mar;28 Suppl 2:S151-60. doi: 110.1097/QAD.0000000000000230. Review.

PMID:
24849475
20.

Early initiation of antiretroviral therapy in HIV-infected adults and adolescents: a systematic review.

Anglemyer A, Rutherford GW, Easterbrook PJ, Horvath T, Vitória M, Jan M, Doherty MC.

AIDS. 2014 Mar;28 Suppl 2:S105-18. doi: 10.1097/QAD.0000000000000232. Review.

PMID:
24849469
21.

The role of mathematical modelling in the development of recommendations in the 2013 WHO consolidated antiretroviral therapy guidelines.

Easterbrook PJ, Doherty MC, Perriëns JH, Barcarolo JL, Hirnschall GO.

AIDS. 2014 Jan;28 Suppl 1:S85-92. doi: 10.1097/QAD.0000000000000111.

PMID:
24468950
22.

Modeling the impact of early antiretroviral therapy for adults coinfected with HIV and hepatitis B or C in South Africa.

Martin NK, Devine A, Eaton JW, Miners A, Hallett TB, Foster GR, Dore GJ, Easterbrook PJ, Legood R, Vickerman P.

AIDS. 2014 Jan;28 Suppl 1:S35-46. doi: 10.1097/QAD.0000000000000084.

PMID:
24468945
23.

The next generation of the World Health Organization's global antiretroviral guidance.

Hirnschall G, Harries AD, Easterbrook PJ, Doherty MC, Ball A.

J Int AIDS Soc. 2013 Jun 30;16:18757. doi: 10.7448/IAS.16.1.18757.

24.

Pre-antiretroviral therapy plasma levels of CCL2 may aid in the prediction of tuberculosis-associated immune reconstitution inflammatory syndrome in HIV patients after they commence antiretroviral therapy.

Oliver BG, Haddow LJ, Agarwal U, Kumar M, Easterbrook PJ, Moosa MY, Singh S, Price P.

J Acquir Immune Defic Syndr. 2013 Jun 1;63(2):e72-4. doi: 10.1097/QAI.0b013e31828e6182. No abstract available.

PMID:
23666138
25.

Immune reconstitution inflammatory syndrome associated with Kaposi sarcoma: higher incidence and mortality in Africa than in the UK.

Letang E, Lewis JJ, Bower M, Mosam A, Borok M, Campbell TB, Naniche D, Newsom-Davis T, Shaik F, Fiorillo S, Miro JM, Schellenberg D, Easterbrook PJ.

AIDS. 2013 Jun 19;27(10):1603-13. doi: 10.1097/QAD.0b013e328360a5a1.

PMID:
23462220
26.

Incidence, clinical spectrum, risk factors and impact of HIV-associated immune reconstitution inflammatory syndrome in South Africa.

Haddow LJ, Moosa MY, Mosam A, Moodley P, Parboosing R, Easterbrook PJ.

PLoS One. 2012;7(11):e40623. doi: 10.1371/journal.pone.0040623. Epub 2012 Nov 12.

27.

Short communication: Plasma levels of vitamin D in HIV patients initiating antiretroviral therapy do not predict immune restoration disease associated with Mycobacterium tuberculosis.

Price P, Haddow LJ, Affandi J, Agarwal U, Easterbrook PJ, Elliott J, French M, Kumar M, Moosa MY, Oliver B, Singh S, Sola M, Saphonn V, Vun MC.

AIDS Res Hum Retroviruses. 2012 Oct;28(10):1216-9. Epub 2012 Mar 13.

PMID:
22280097
28.

Trends in the clinical characteristics of HIV-infected patients initiating antiretroviral therapy in Kenya, Uganda and Tanzania between 2002 and 2009.

Geng EH, Hunt PW, Diero LO, Kimaiyo S, Somi GR, Okong P, Bangsberg DR, Bwana MB, Cohen CR, Otieno JA, Wabwire D, Elul B, Nash D, Easterbrook PJ, Braitstein P, Musick BS, Martin JN, Yiannoutsos CT, Wools-Kaloustian K.

J Int AIDS Soc. 2011 Sep 28;14:46. doi: 10.1186/1758-2652-14-46.

29.

Global health in the UK government and university sector.

Coltart CE, Black ME, Easterbrook PJ.

Infect Dis Clin North Am. 2011 Sep;25(3):555-74, viii. doi: 10.1016/j.idc.2011.08.001. Review.

PMID:
21896358
30.

Institutional partnerships in global health.

Easterbrook PJ.

Clin Med (Lond). 2011 Apr;11(2):112-3. No abstract available.

31.

Circulating inflammatory biomarkers can predict and characterize tuberculosis-associated immune reconstitution inflammatory syndrome.

Haddow LJ, Dibben O, Moosa MY, Borrow P, Easterbrook PJ.

AIDS. 2011 Jun 1;25(9):1163-74. doi: 10.1097/QAD.0b013e3283477d67.

PMID:
21505297
32.

Sexual risk behaviours and sexual health outcomes among heterosexual black Caribbeans: comparing sexually transmitted infection clinic attendees and national probability survey respondents.

Gerver SM, Easterbrook PJ, Anderson M, Solarin I, Elam G, Fenton KA, Garnett G, Mercer CH.

Int J STD AIDS. 2011 Feb;22(2):85-90. doi: 10.1258/ijsa.2010.010301.

PMID:
21427429
33.

Quality of data collection in a large HIV observational clinic database in sub-Saharan Africa: implications for clinical research and audit of care.

Kiragga AN, Castelnuovo B, Schaefer P, Muwonge T, Easterbrook PJ.

J Int AIDS Soc. 2011 Jan 20;14:3. doi: 10.1186/1758-2652-14-3.

34.

Cryptococcal immune reconstitution inflammatory syndrome in HIV-1-infected individuals: proposed clinical case definitions.

Haddow LJ, Colebunders R, Meintjes G, Lawn SD, Elliott JH, Manabe YC, Bohjanen PR, Sungkanuparph S, Easterbrook PJ, French MA, Boulware DR; International Network for the Study of HIV-associated IRIS (INSHI).

Lancet Infect Dis. 2010 Nov;10(11):791-802. doi: 10.1016/S1473-3099(10)70170-5.

35.

High rate of loss to clinical follow up among African HIV-infected patients attending a London clinic: a retrospective analysis of a clinical cohort.

Gerver SM, Chadborn TR, Ibrahim F, Vatsa B, Delpech VC, Easterbrook PJ.

J Int AIDS Soc. 2010 Aug 4;13:29. doi: 10.1186/1758-2652-13-29.

36.

Impact of HIV-1 viral subtype on disease progression and response to antiretroviral therapy.

Easterbrook PJ, Smith M, Mullen J, O'Shea S, Chrystie I, de Ruiter A, Tatt ID, Geretti AM, Zuckerman M.

J Int AIDS Soc. 2010 Feb 3;13:4. doi: 10.1186/1758-2652-13-4.

37.

Validation of a published case definition for tuberculosis-associated immune reconstitution inflammatory syndrome.

Haddow LJ, Moosa MY, Easterbrook PJ.

AIDS. 2010 Jan 2;24(1):103-8. doi: 10.1097/QAD.0b013e32832ec1f4.

PMID:
19926965
38.

Defining immune reconstitution inflammatory syndrome: evaluation of expert opinion versus 2 case definitions in a South African cohort.

Haddow LJ, Easterbrook PJ, Mosam A, Khanyile NG, Parboosing R, Moodley P, Moosa MY.

Clin Infect Dis. 2009 Nov 1;49(9):1424-32. doi: 10.1086/630208.

PMID:
19788360
39.

The challenge of HIV-1 antiretroviral resistance in Africa in the era of HAART.

Sendagire H, Easterbrook PJ, Nankya I, Arts E, Thomas D, Reynolds SJ.

AIDS Rev. 2009 Apr-Jun;11(2):59-70. Review.

40.

Immune reconstitution disease associated with mycobacterial infections.

Lawn SD, Lipman MC, Easterbrook PJ.

Curr Opin HIV AIDS. 2008 Jul;3(4):425-31. doi: 10.1097/COH.0b013e3282fe99dc.

PMID:
19373001
41.

Sub-optimal CD4 reconstitution despite viral suppression in an urban cohort on antiretroviral therapy (ART) in sub-Saharan Africa: frequency and clinical significance.

Nakanjako D, Kiragga A, Ibrahim F, Castelnuovo B, Kamya MR, Easterbrook PJ.

AIDS Res Ther. 2008 Oct 28;5:23. doi: 10.1186/1742-6405-5-23.

42.

Systematic review of the empirical evidence of study publication bias and outcome reporting bias.

Dwan K, Altman DG, Arnaiz JA, Bloom J, Chan AW, Cronin E, Decullier E, Easterbrook PJ, Von Elm E, Gamble C, Ghersi D, Ioannidis JP, Simes J, Williamson PR.

PLoS One. 2008 Aug 28;3(8):e3081. doi: 10.1371/journal.pone.0003081. Review.

43.

Pneumonia in HIV-infected persons: increased risk with cigarette smoking and treatment interruption.

Gordin FM, Roediger MP, Girard PM, Lundgren JD, Miro JM, Palfreeman A, Rodriguez-Barradas MC, Wolff MJ, Easterbrook PJ, Clezy K, Slater LN.

Am J Respir Crit Care Med. 2008 Sep 15;178(6):630-6. doi: 10.1164/rccm.200804-617OC. Epub 2008 Jul 10.

44.

Predictors of renal outcome in HIV-associated nephropathy.

Post FA, Campbell LJ, Hamzah L, Collins L, Jones R, Siwani R, Johnson L, Fisher M, Holt SG, Bhagani S, Frankel AH, Wilkins E, Ainsworth JG, Larbalestier N, Macallan DC, Banerjee D, Baily G, Thuraisingham RC, Donohoe P, Hendry BM, Hilton RM, Edwards SG, Hangartner R, Howie AJ, Connolly JO, Easterbrook PJ.

Clin Infect Dis. 2008 Apr 15;46(8):1282-9. doi: 10.1086/529385.

PMID:
18444868
45.

HIV immune reconstitution syndrome in sub-Saharan Africa.

Easterbrook PJ.

AIDS. 2008 Mar 12;22(5):643-5. doi: 10.1097/QAD.0b013e3282f4a621. No abstract available.

PMID:
18317006
46.

Patterns and predictors of the use of different antiretroviral drug regimens at treatment initiation in the UK.

Easterbrook PJ, Phillips AN, Hill T, Matthias R, Fisher M, Gazzard B, Gilson R, Scullard G, Johnson M, Dunn DT, Orkin C, Anderson J, Schwenk A, Leen C, Sabin CA; UK Collaborative HIV Cohort (CHIC) Study Steering Committee.

HIV Med. 2008 Jan;9(1):47-56. doi: 10.1111/j.1468-1293.2008.00512.x.

47.

Evidence for onward transmission of HIV-1 non-B subtype strains in the United Kingdom.

Aggarwal I, Smith M, Tatt ID, Murad S, Osner N, Geretti AM, Easterbrook PJ.

J Acquir Immune Defic Syndr. 2006 Feb 1;41(2):201-9.

PMID:
16394853
48.

Incidence and risk factors for immune reconstitution inflammatory syndrome in an ethnically diverse HIV type 1-infected cohort.

Ratnam I, Chiu C, Kandala NB, Easterbrook PJ.

Clin Infect Dis. 2006 Feb 1;42(3):418-27. Epub 2005 Dec 28.

PMID:
16392092
49.

CD8+ T cell epitope-flanking mutations disrupt proteasomal processing of HIV-1 Nef.

Milicic A, Price DA, Zimbwa P, Booth BL, Brown HL, Easterbrook PJ, Olsen K, Robinson N, Gileadi U, Sewell AK, Cerundolo V, Phillips RE.

J Immunol. 2005 Oct 1;175(7):4618-26.

50.

Supplemental Content

Loading ...
Support Center